311 related articles for article (PubMed ID: 35978812)
1. Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.
Zhang Z; Li D; Yun H; Tong J; Liu W; Chai K; Zeng T; Gao Z; Xie Y
Front Oncol; 2022; 12():923260. PubMed ID: 35978812
[TBL] [Abstract][Full Text] [Related]
2. Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.
Li H; Wang S; Yang Z; Meng X; Niu M
Bioact Mater; 2024 Jun; 36():376-412. PubMed ID: 38544737
[TBL] [Abstract][Full Text] [Related]
3. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers.
Zhang H; Feng Q; Chen WD; Wang YD
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360560
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan metabolism in digestive system tumors: unraveling the pathways and implications.
Yu L; Lu J; Du W
Cell Commun Signal; 2024 Mar; 22(1):174. PubMed ID: 38462620
[TBL] [Abstract][Full Text] [Related]
5. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
[TBL] [Abstract][Full Text] [Related]
6. Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures.
Furlan A; Roux B; Lamballe F; Conti F; Issaly N; Daian F; Guillemot JF; Richelme S; Contensin M; Bosch J; Passarella D; Piccolo O; Dono R; Maina F
PLoS One; 2012; 7(10):e46738. PubMed ID: 23071625
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of MET in gastric cancer.
Inokuchi M; Otsuki S; Fujimori Y; Sato Y; Nakagawa M; Kojima K
World J Gastrointest Oncol; 2015 Nov; 7(11):317-27. PubMed ID: 26600931
[TBL] [Abstract][Full Text] [Related]
8. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.
Glodde N; Bald T; van den Boorn-Konijnenberg D; Nakamura K; O'Donnell JS; Szczepanski S; Brandes M; Eickhoff S; Das I; Shridhar N; Hinze D; Rogava M; van der Sluis TC; Ruotsalainen JJ; Gaffal E; Landsberg J; Ludwig KU; Wilhelm C; Riek-Burchardt M; Müller AJ; Gebhardt C; Scolyer RA; Long GV; Janzen V; Teng MWL; Kastenmüller W; Mazzone M; Smyth MJ; Tüting T; Hölzel M
Immunity; 2017 Oct; 47(4):789-802.e9. PubMed ID: 29045907
[TBL] [Abstract][Full Text] [Related]
9. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
Front Oncol; 2022; 12():844260. PubMed ID: 35433470
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
11. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
[TBL] [Abstract][Full Text] [Related]
13. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Yuan Q; Liang Q; Sun Z; Yuan X; Hou W; Wang Y; Wang H; Yu M
Oncoimmunology; 2021; 10(1):1914954. PubMed ID: 34350059
[TBL] [Abstract][Full Text] [Related]
14. HGF/c-Met Axis: The Advanced Development in Digestive System Cancer.
Shao Z; Pan H; Tu S; Zhang J; Yan S; Shao A
Front Cell Dev Biol; 2020; 8():801. PubMed ID: 33195182
[TBL] [Abstract][Full Text] [Related]
15. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
16. c-Met expression in renal cell carcinoma with bone metastases.
Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
[TBL] [Abstract][Full Text] [Related]
17. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
Zhang YW
World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
[TBL] [Abstract][Full Text] [Related]
18. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
[TBL] [Abstract][Full Text] [Related]
19. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
20. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
